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Huntington’s disease is a fatal neurodegenerative
disease, where dysfunction and loss of striatal and
cortical neurons are central to the pathogenesis of
the disease. Here, we integrated quantitative studies
to investigate the underlying mechanisms behind HD
pathology in a systems-widemanner. To this end, we
used state-of-the-art mass spectrometry to establish
a spatial brain proteome from late-stage R6/2 mice
and compared this with wild-type littermates. We
observed altered expression of proteins in pathways
related to energy metabolism, synapse function, and
neurotransmitter homeostasis. To support these
findings, metabolic 13C labeling studies confirmed a
compromised astrocytic metabolism and regulation
of glutamate-GABA-glutamine cycling, resulting in
impaired release of glutamine and GABA synthesis.
In recent years, increasing attention has been
focused on the role of astrocytes in HD, and our
data support that therapeutic strategies to improve
astrocytic glutamine homeostasis may help amelio-
rate symptoms in HD.
INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder characterized by loss of voluntary motor
control, psychiatric disturbances, and cognitive decline. The
symptoms start in mid-life and are followed by a gradual decline,
leading to death 15–20 years after the onset of symptoms (Ross
and Tabrizi, 2011). The disease is caused by an expansion of the
CAG repeat in the huntingtin (HTT) gene, causing an elongation
of the polyglutamine tract in the ubiquitously expressed hunting-
tin protein (HTT) (Novak and Tabrizi, 2010). Despite the predictive
ability to identify mutation carriers before disease onset, there is
currently no therapy available that can delay the onset or slow
disease progression of HD. However, after many years of pre-Cell
This is an open access article undclinical development, promising results have been observed in
the first human gene therapy trial to lower the toxic mutant
HTT protein. The mutant HTT protein causes neuropathology
with a reduction of the striatum and thinning of the cortex, start-
ing more than a decade before the appearance of the symptoms
(Aylward et al., 2011). In particular, neurons of the striatum and
neurons that project from the cortex to the striatum are more
susceptible to mutant HTT (Rosas et al., 2008; Aylward et al.,
2012). The basis of the selective neuronal vulnerability in HD
remains elusive butmay in part be explained by defects in energy
metabolism, especially since it has become evident that ener-
getic malfunctions are present in the HD brain andmay be a cen-
tral mechanism in HD pathology (Browne and Beal, 2004; Kim
et al., 2010; Mochel et al., 2012; Tang et al., 2013). This notion
is not unique to HD, and the high demand of the cerebral meta-
bolic machinery and impairments in brain energy and neuro-
transmitter metabolism have been linked to several neurological
diseases (Attwell and Laughlin, 2001; Mergenthaler et al., 2013;
Camandola and Mattson, 2017). In recent years, attention has
shifted from a neuron-centric focus to the role of glial cells and
especially astrocytes in HD (Acun˜a et al., 2013; Tong et al.,
2014; Benraiss et al., 2016; Khakh et al., 2017). In the brain, as-
trocytes are the most abundant cell type and are tightly
associated with the synapse, where they are responsible for
modulating synaptic transmission as well as providing metabolic
support to the neurons (Be´langer et al., 2011). Astrocytes play a
crucial role in up-take of the neurotransmitter glutamate and
providing neurons with glutamine, an important precursor for
glutamate and gamma-aminobutyric acid (GABA) synthesis
(called the glutamate-GABA-glutamine cycle) (Sonnewald
et al., 1993; Bak et al., 2006b).
To get a better understanding of the molecular pathogenesis
of HD, we first performed a systems-wide exploration of protein
changes in four brain regions (striatum, cortex, hippocampus,
and midbrain) from 12-week-old transgenic R6/2 mice. Notably,
R6/2 mice recapitulate several HD phenotypes, including move-
ment disturbances, muscle wasting, and premature death at
about 14 to 16 weeks (Mangiarini et al., 1996), and, therefore,
constitute a commonly used HD model system (Menalled and
Brunner, 2014). To this end, we applied an unbiased andReports 23, 2211–2224, May 15, 2018 ª 2018 The Author(s). 2211
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
systems-wide proteomics strategy recently described for deter-
mination of quantitative brain analyses (Sharma et al., 2015).
Using this strategy, we identified 6,801 proteins and quantified
their expression changes across the different brain regions.
Reassuringly, we observed the most aberrant expression
changes in the striatum and cortex. Among the differentially
regulated proteins, we found significant enrichment of proteins
belonging to several pathways relevant for glutamate signaling,
synapse function, and neurotransmitter homeostasis. Moreover,
several protein changes in key metabolic pathways, including
glycolysis, the tricarboxylic acid (TCA) cycle, and the gluta-
mate-GABA-glutamine cycle, were observed. Our findings are
supported by a recent temporal study where proteomic analyses
demonstrated that a large number of proteins with potential links
to HD accumulate in aggregates (Hosp et al., 2017), including
some of the key candidates identified in this study. Based on
our findings, we conducted functional metabolic analyses on
acutely isolated brain slices from the striatum and cortex using
stable 13C-labeled energy substrates coupled to gas chroma-
tography-mass spectrometry (GC-MS) analyses. The metabolic
experiments supported our proteomics findings and demon-
strated that astrocytic metabolism and neurotransmitter dy-
namics are impaired whereas neuronal metabolism seems
largely unaffected under our conditions.
RESULTS
Spatial Brain Proteome in the R6/2 Mouse
To map the spatial brain proteome, we microdissected the
brains of four wild-type (WT) and R6/2 mice into four central
regions (striatum, cortex, hippocampus, and midbrain) and sub-
sequently profiled protein expression changes by MS analysis
(Figure 1A; Table S1). To establish a baseline for the technical
and biological quality, we first evaluated theWT proteome sepa-
rately (Figure S1A). We found a strong correlation between rep-
licates (Pearson correlation ranging from0.97–0.99) (Figure S1B),
and the high reproducibility in our analysis was further supported
by a principal-component analysis (PCA) detailing a clear sepa-
ration of the four different brain regions (Figures S1C and S1D).
To assess the biological background, we next performed a mul-
tiple comparisons analysis test to identify significant protein
changes across the four brain regions (Figure S1E; Table S2).
Collectively, the expression profiles from the striatum, cortex,
and hippocampus clustered well together compared with the
midbrain, with gene ontology (GO) enrichment and pathway an-
alyses revealing 9 clusters to be enriched across the individual
brain regions (Table S2; Figure S1E). Collectively, these results
are comparable with previous observations from a deep brain
proteome study (Sharma et al., 2015) and confirm the reliability
of our analytical strategy.
Having established the spatial brain proteome forWTmice, we
next investigated the brain proteome from 12-week-old R6/2
mice with 190–200 CAG repeats (Reynolds et al., 2017) in a
similar manner. Thesemice display progressive clasping starting
at 8 weeks of age, with a complete clasping phenotype at
11 weeks of age (Figure S2), similar to previous observations
for the R6/2 mouse with 160 CAG repeats (Cummings et al.,
2012). In total, we identified 6,801 proteins, and 5,555 were2212 Cell Reports 23, 2211–2224, May 15, 2018selected for further investigations (Figure 1B; Table S1), with
most of these proteins being comparable with proteins found
in a recent temporal proteome study of the R6/2 mouse carrying
a 150-CAG repeat expansion (Hosp et al., 2017). The majority of
the selected proteins in our study were shared between all four
brain regions across the two genotypes (Figure S1F), and, similar
to the data obtained from WT mice, we observed strong repro-
ducibility (Pearson correlations ranging from 0.96–0.99) between
biological replicates (Figure 1C). Moreover, a three-dimensional
PCA visualization showed a clear separation of brain regions and
genotype (Figure 1D; Figures S1G and S1H), supporting that
our proteomic analysis provides a sound basis for genotypic
comparison.
Having established good reproducibility in our experimental
setup and having validated that a quantitative comparison of
spatial proteomes between WT and R6/2 brains is well founded,
we next performed a systems-wide comparison of all brain re-
gions and genotypes. Upon hierarchical clustering of HD and
WT data, we observed that biological replicates, individual brain
regions, and genotypes clustered strongly together (Figure 1E;
Table S2). Several of the regulated protein clusters were en-
riched for terms previously associated with HD, including the
glutamate signaling pathway (p = 1.043 107), protein oligomer-
ization (p = 1.033 105), and the proteasome (p = 1.023 1020)
(Zuccato et al., 2010; Bates et al., 2015), whereas processes
previously only gaining little attention included extracellular ve-
sicular exosome (p = 8.87 3 107), divalent metal ion transport
(p = 2.053 107), andmetabolism of amino acids and derivatives
(p = 1.59 3 1012) (Figure 1F). Because of the spatial HD signa-
ture, we decided to investigate the individual brain regions in
more detail (Figure 2A; Table S3). Across the four brain regions,
we identified several protein changes, with a total of 750 and 764
proteins exhibiting increased or decreased expression, respec-
tively, in R6/2 mice compared with the WT (Figure 2B). More
specifically, the individual brain regions striatum, cortex, hippo-
campus, and midbrain exhibited 905, 779, 385, and 114 protein
changes, respectively, which clearly reflects the vulnerability of
the brain regions to the presence of mutant HTT (striatum > cor-
tex >> hippocampus >>> midbrain). Moreover, the observed
proteome changes are comparable with the number of differen-
tially expressed genes in two R6/2 mouse models with 150 and
300 CAG repeats, respectively (Tang et al., 2011).
Among the regulated proteins (false discovery rate [FDR] >
0.05), we observed several candidates previously associated
with HD (Zuccato et al., 2010; Bates et al., 2015). For example,
we found a marked reduction in phosphodiesterase 10A
(PDE10A) expression in the striatum and cortex, which is central
for neuronal survival and an early marker of disease progression
(Wilson et al., 2016). Similarly, we found a reduction in dopa-
mine- and cyclic AMP (cAMP)-regulated phosphoprotein
32 kDa (DARPP-32) in the striatum and cortex, which is often
used as a marker of medium spiny neuron (MSN) atrophy and
neurodegeneration (Guo et al., 2012). Microtubule-associated
protein tau (MAPT) expression was increased in the striatum
and cortex, which is intriguing considering MAPT levels in cere-
brospinal fluid, and has been suggested as a potential biomarker
able to predict clinical phenotype in HD patients (Rodrigues
et al., 2016). In addition, HAP1 (huntingtin-associated protein 1),
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Figure 1. Spatial Protein Expression
(A) Brains from 12-week-old R6/2 mice were
collected and micro-dissected into 4 brain regions
(striatum, cortex, hippocampus, and midbrain)
and subjected to LC-MS analysis with subsequent
data analysis using MaxQuant and Perseus soft-
ware. In addition, brain slices were isolated from
the striatum and cortex, respectively, and used for
metabolic 13C labeling and subjected to GC-MS.
(B) The total number of identified proteins before
and after filtering (3 of 4).
(C) Diagram displaying the Pearson correlation
between the individual samples from the 4 regions
and the 2 genotypes.
(D) PCA (principal-component analysis) demon-
strating the difference of the 4 different regions
and 2 genotypes using three PCs (principal com-
ponents): PC1, PC2, and PC4.
(E) Cluster analysis demonstrating the grouping of
the replicate samples and 8 clusters with signifi-
cantly enriched pathways related to brain region
and genotype of a total of 13 clusters.
(F) Expression levels are illustrated for 4 selected
clusters, including glutamate signaling (10 genes,
Benjamini-Hochberg p = 1.04E03), protein olig-
omerization (13 genes, Benjamini-Hochberg
p = 3.59E02), proteasome (18 genes, Benjamini-
Hochberg p = 1.97E16), and extracellular ve-
sicular exosome (90 genes, Benjamini-Hochberg
p = 1.11E03), and both genotypic and tissue-
specific differences can be observed. Proteins
belonging to the selected annotation are shown in
purple, and proteins belonging to the cluster are
shown in yellow to green based on distance from
the mean of all proteins in the cluster.which participates in intracellular vesicle transport (Wu and
Zhou, 2009), showed increased expression across all regions
except the midbrain. Moreover, three proteins from the Serpine
superfamily (SERPIN A3M, -A3K, and -A1E), which are murine
paralogs to the human a1-antichymotrypsin and a1-antitrypsin,
were decreased in all brain regions, consistent with a previous
study showing decreased a 1-antitrypsin in R6/2 and human
HD brains (Zabel et al., 2002). Collectively, our findings demon-
strate several similarities at the molecular level between R6/2
mice and HD patients and support the strong foundation of our
study.Cell RNext we performed a pathway enrich-
ment analysis (Table S3). To encapsulate
the commonalities of the changed pro-
cesses across the brain regions, we
condensed the data and visualized the
GO terms for cellular components
(GOCCs) and biological processes
(GOBPs) as individual networks (Figures
2C and 2D; Table S4; Figures S2 and
S3). The majority of the terms were
strongly associated with synapse struc-
ture, function, and transmission, which il-
lustrates the essential role of the synapse
in the pathogenesis of HD. Importantly,synapse function is tightly coupled to energy metabolism as
the restoration of ion gradients after action potentials as well
as uptake and recycling of neurotransmitters are some of the
main processes contributing to the high energy demand of the
brain (Harris et al., 2012). In support of this notion, we observed
several dysregulated proteins in the R6/2 mouse related to en-
ergy metabolism, including glycolysis, the TCA cycle, and the
glutamate-GABA-glutamine cycle (Figure 3). This list of proteins
included several key proteins predominantly confined to astro-
cytes, including the glutamate transporter excitatory amino
acid transporter 2 (EAAT2) (Bak et al., 2006b; Be´langer et al.,eports 23, 2211–2224, May 15, 2018 2213
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Figure 2. Protein Changes in Huntington’s
Disease
(A) Volcano plots illustrate the significant protein
expression changes. The top 10 proteins with the
highest or lowest fold difference aremarked on the
blot for all 4 brain regions (FDR > 0.05).
(B) 764 and 750 proteins show decreased
and increased expression in HD tissues, respec-
tively. Shown is the number of enriched pathways
across the 4 regions based on proteins with
either increased (orange) or decreased (blue)
expression.
(C and D) Networks built on enriched GOCC terms
(C) and GOBP terms (D) for a representative
visualization of the changes in the HD brain. All 11
identified clusters are shown for GOCC, whereas
the selected terms are shown for GOBP (Figures
S3 and S4). Yellow nodes represent the different
brain regions, and the size of the node illustrates
the number of changed proteins for each region.
The remaining colored nodes represent the indi-
vidual enriched terms, and the size of the node
marks the enrichment factor for that specific
annotation term (Table S4). The lines illustrate the
number of associated proteins for each annotation
term. Blue lines represent proteins with decreased
expression in HD compared with the WT, whereas
red lines represent proteins with increased
expression. The thickness of the lines illustrates
the number of proteins connecting the brain re-
gions to the annotation term.2011), glutamine synthetase (GS) (Walls et al., 2015), and the
glutamine transporter sodium-coupled neutral amino acid trans-
porter 3 (SNAT3) (Leke and Schousboe, 2016; Todd et al., 2017).
Collectively, the observed expression changes pointed toward
impaired astrocytic metabolism and function. However, since
differentially regulated proteins and enzymesmay still retain their
function and catalytic activity, we decided to investigate the en-
ergy and neurotransmitter metabolism in acutely isolated brain
slices to better understand the functional consequences of the
observed protein dysregulation. Here, we applied brain slices
from the two most affected regions (striatum and cortex) to
obtain functional ex vivo 13C labeling data using substrates
that could distinguish between the astrocytic and neuronal
compartments.2214 Cell Reports 23, 2211–2224, May 15, 2018Energy and Neurotransmitter
Metabolism in R6/2 Mice
To establish a baseline for our meta-
bolic brain slice experiments, we first
measured a panel of amino acids using
high-performance liquid chromatography
(HPLC) in extracts of freshly prepared
cortical and striatal slices from 12-week-
old R6/2 and WT mice (Andersen et al.,
2017b). Overall, we found that glutamine
levels were significantly elevated in
cortical slices (p = 0.048), with a similar
tendency present in striatal slices (p =
0.124) from R6/2 mice compared withthe WT (Table S5). Likewise, we observed increased taurine
levels in striatal (p = 0.021) and cortical (p = 0.019) slices from
R6/2mice. This observation is in linewith previous studies estab-
lishing that elevated levels of taurine and glutamine are robust in-
dictors of disease progression in both the striatum and cortex of
R6/2 mice (Behrens et al., 2002; Tkac et al., 2007; Zacharoff
et al., 2012).
To study energy metabolism in the isolated brain slices and to
provide detailed insights into relevant metabolic pathways, we
next used 13C-labeled energy substrates and GC-MS analysis
to quantify 13C incorporation in central cellular metabolites
(Andersen et al., 2017a). To this end, we incubated the slices at
37C for 60 min with 13C-labeled glucose and b-hydroxybutyrate
(bHB) (McNair et al., 2017), which are metabolized to a greater
A B
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Figure 3. Energy Metabolism in Hunting-
ton’s Disease
(A) Three central pathways for cerebral metabolism
are illustrated with the associated key enzymes
marked at each step. Glycolysis and the TCA cycle
take place in both astrocytes and neurons but are
only illustrated on the left (astrocyte) for simplicity.
Substrates are marked in bold, and enzymes and
transporter proteins are marked in italic font. Pro-
teins with decreased expression in HD compared
with the WT are marked in blue, whereas proteins
with increased expression are marked in red.
Proteins marked in gray were not quantified in our
study. Proteins with preferential or confined
expression to either astrocytes or neurons are
marked with 1 or 2, respectively.
(B and C) The results for the glycolytic enzymes (B)
and proteins involved in glutamate-glutamine-
GABA cycling (C) are graphed for comparison
across the different brain regions.
Data are represented as mean ± SEM. Signifi-
cance with p% 0.05 is marked by an asterisk (n = 4
for each group).extent in neurons compared with glial cells and, therefore, pri-
marily reflect neuronal metabolism (Bak et al., 2006a; Achanta
et al., 2017; Dı´az-Garcı´a et al., 2017). In our metabolic analysis,
we observedminor changes in 13C labeling of striatal and cortical
slices incubated with either [U-13C]bHB (Figure 4, blue bars) or
[U-13C]glucose (Figure S4, blue bars; Table S6). From the
measured metabolism of [U-13C]bHB, a slight decrease in gluta-
mate 13C labeling was observed in both the striatum (p = 0.0026)
and cortex (p = 0.0049), along with decreased glutamine 13C
labeling in the striatum (p = 0.0425). The slight reduction in gluta-
mate labeling was also observed from the metabolism of [U-13C]
glucose in striatal (p =0.030) andcortical slices (p =0.0492) ofR6/
2 mice. Collectively, these results indicate that the neuronal
metabolism of glucose and bHB is largely preserved in R6/2
mice despite the reduced expression of glycolytic enzymes (Fig-
ure 3B). In contrast, when we used [1,2-13C]acetate, which isCell Rmetabolized preferentially in astrocytes
and can be used as a metabolic marker
of this compartment (Badar-Goffer et al.,
1990; Sonnewald et al., 1993), we
observed large reductions in 13C labeling
of a-ketoglutarate (p = 0.0023), aspartate
(p = 0.0030), and glutamate (p = 0.0151)
in striatal slices from R6/2 mice (Figure 4,
green bars; Table S6). The decreased
13C labeling in glutamate is likely linked
to hampered astrocytic TCA cycle meta-
bolism, as characterized by lower 13C
labeling in aspartate and a-ketoglutarate
from [1,2-13C]acetate metabolism. A
similar trend was observed for cortical sli-
ces but did not reach statistical signifi-
cance, whereas significant reductions
in 13C labeling of glutamine and GABA
were observed in both the striatum (p =5.52 x 10-4 and 5.19 x 10-7, respectively) and cortex (p = 0.0043
and 0.0071, respectively). Considering that glutamine is exclu-
sively synthesized in astrocytes and the main precursor for
GABA synthesis in neurons (Sonnewald et al., 1993; Andersen
et al., 2017b), our results indicate that limited amounts of gluta-
mine reach the neuronal compartment. This reduction may
stem from a lower availability of glutamate for glutamine synthe-
sis, impaired synthesis of glutamine, reduced transfer of gluta-
mine from the astrocyte to the neuron, or a permutation of them
all. Interestingly, all three mechanisms are individually supported
by our spatial proteome analysis, where we found a reduction in
the expression of both the glutamate transporter EAAT2, the
glutamine synthetase GS, and the glutamine transporter SNAT3
(Figure 3C).
To further investigate the compromised astrocytic energy
metabolism, we next sought to specifically map the metabolismeports 23, 2211–2224, May 15, 2018 2215
Figure 4. Metabolism of b-Hydroxybutyrate and Acetate
Brains slices were prepared from the striatum and cortex of 12-week-old R6/2 andWTmice and incubated inmedium containing [U-13C]b-hydroxybutyrate (bHB)
(blue columns) and [1,2-13C]acetate (green columns). bHB is metabolized predominantly in neurons, whereas acetate is preferentially metabolized in astrocytes.
Hence, these substrates can be used as metabolic markers of these two compartments. 13C incorporation was measured with GC-MS. Data are represented as
mean ± SEM. *p% 0.05 (n = 6 for each group). Additional information for GC-MS can be found in Table S6.of glutamate and glutamine, which are key constituents of both
neurotransmission and cerebral amino acid homeostasis (Al-
brecht et al., 2010; Walls et al., 2015). Released neurotransmitter
glutamate is primarily removed from the synapse by adjacent as-
trocytes (Be´langer et al., 2011). In the astrocytes, glutamate can
be converted into glutamine or used for other purposes,
including cellular energy metabolism. Glutamine synthesized in
the astrocyte is transported to neurons and converted into
glutamate for oxidative metabolism or neurotransmission (Fig-
ure 3). Overall, we observed no changes in the metabolism of
glutamine (Figure 5, orange bars; Figure S6), whereas uptake
of [U-13C]glutamate was slightly decreased in cortical slices
(p = 0.0133) fromR6/2 mice (Figure 5, red bars; Figure S6), which
agrees with reduced expression of the glutamate transporter
EAAT2. In addition, striatal reductions in 13C labeling of the
TCA cycle intermediates a-ketoglutarate (p = 0.0462), fumarate
(p = 0.0319), and citrate (p = 0.0106) were observed, and
reduced 13C labeling of aspartate was found in both striatal2216 Cell Reports 23, 2211–2224, May 15, 2018(p = 0.0050) and cortical slices (p = 0.0423) from R6/2 mice
compared with the WT. As observed for incubation with
[1,2-13C]acetate, 13C labeling of GABA from the metabolism of
[U-13C]glutamate was significantly reduced in both the striatum
(p = 0.0052) and cortex (p = 0.0166), indicating that malfunctions
in the astrocytic compartment affect the synthesis of this central
inhibitory neurotransmitter. This notion is supported by elevated
absolute levels of glutamine after incubation with [U-13C]gluta-
mate (Table S5), indicating sufficient glutamine synthesis,
whereas impaired release of glutamine from astrocytes likely
leads to its accumulation, hampering neuronal GABA synthesis.
DISCUSSION
Here, we describe an integrative analysis of regulated differ-
ences in the proteome andmetabolic and neurotransmitter inter-
mediates in the brain of R6/2 mice compared with WT litter-
mates. Our proteome analysis demonstrated that key proteins
Figure 5. Metabolism of Glutamate and Glutamine
Brains slices were prepared from the striatum and cortex of 12-week-old R6/2 and WT mice and incubated in medium containing [U-13C]glutamine (orange
columns) and [U-13C]glutamate (red columns). Glutamine is metabolized predominantly in neurons, whereas glutamate is preferentially taken up andmetabolized
in astrocytes. Hence, these substrates can be used as metabolic markers of these two compartments. 13C incorporation was measured with GC-MS. Data are
represented as mean ± SEM. *p% 0.05 (n = 6 for each group). Additional information for GC-MS can be found in Table S6.involved in synapse function and energy metabolism are dysre-
gulated, which led us to further investigate the consequences of
these changes at the level of energy metabolism and amino acid
homeostasis. To this end, we used ex vivo brain slices that
demonstrated impaired glial metabolism, resulting in hampered
neuronal GABA synthesis, likely as a consequence of reduced
glutamine release by astrocytes.
We used state-of-the-art MS technology to investigate molec-
ular changes in the R6/2 HD mouse model with 190–200 CAG
repeats at the age of 12 weeks (Reynolds et al., 2017), which cor-
responds to the late stages of the disease. These mice demon-
strate a similar progression in behavior as mice with 150 CAG
repeats (Cummings et al., 2012; Figure S1) and a similar severity
of molecular changes (Tang et al., 2011). Furthermore, we found
elevatedcerebral levelsof taurine (TableS5),whichhaspreviously
been demonstrated to be a robustmarker of disease progression,
in theR6/2mouse,manifestingaround8–9weeksof age (Behrens
et al., 2002; Tsang et al., 2006; Zacharoff et al., 2012).
Previously, MS-based studies have been conducted to map
protein expression changes across several different HD models,
including R6/2 (Perluigi et al., 2005; Liu et al., 2007; Zabel et al.,
2009; Hosp et al., 2017), Q92 and Q150 (Deschepper et al.,2012), and YAC128 (Wegrzynowicz et al., 2012) mice as well
as an HD rat model (Cong et al., 2012). Although these studies
reported interesting and supportive observations, they did not
focus on the metabolic aspects of astrocytes described here.
Furthermore, we included analysis of the midbrain region in our
study, not previously investigated by proteomics, and thereby
provide an additional resource to the research community.
Initially, we validated our experimental approach by demon-
strating a strong technical and biological reproducibility across
brain regions, which allowed a clear separation of regions and
genotypes (Figures 2C and 2D). Reassuringly, the data demon-
strated that the striatum is the most affected region at the prote-
ome level, whereas the midbrain entails the least expression
differences (Figure 2A), which is in linewith general HD pathology
(Waldvogel et al., 2015). This was also supported by our meta-
bolic studies, where metabolism of the striatal slices was more
affected compared with cortical slices in the R6/2 mice. In the
striatum, we found, in total, 905 proteins with altered expression
in R6/2 compared with WT mice, which supports that the
analyzed mice were in the late stages of the disease. The scale
of molecular changes is supported by a gene profiling study in
the R6/2 mouse with 150 CAG repeats (Tang et al., 2011), whereCell Reports 23, 2211–2224, May 15, 2018 2217
997 differentially regulated genes were observed in the striatum
from 12-week-old mice. Importantly, when we compared the
identified proteins with previous HD studies, we reassuringly
found that several of the dysregulated proteins (Figure 2A;
Table 1) have been associated with HD, including PDE10A,
DARPP-32, HAP1, MAPT, and SERPIN-A1E (Zuccato et al.,
2010; Bates et al., 2015), serving as strong corroboration of
our proteome study. Moreover, the top 20 protein candidates
from a recent proteome study in R6/2 mice with 150 CAG re-
peats, which were selected based on their similarity to the
expression profile of PDE10A, were all confirmed in our dataset
and served as a solid validation of the two independent studies
(Hosp et al., 2017).
Overall, proteins with decreased expression were mostly
related to biological processes such as synapse function and
neurotransmitter homeostasis, whereas proteins with increased
expression belonged to a few processes, including chromatin
regulation and the proteasomal machinery (Figures 2D and 2E;
Table S4). From our detailed analysis of proteins involved in en-
ergy metabolism and amino acid homeostasis, we observed
several changes in key proteins involved in glycolysis, the TCA
cycle, and glutamate-GABA-glutamine cycling (Figure 3). To
corroborate our findings, we investigated the temporal expres-
sion profiles of key proteins using recently published proteome
data (Hosp et al., 2017). Here, we found an overall strong corre-
lation between the two datasets (Figure 3; Figure S5) and
observed that the glycolytic enzymes aldolase C (ALDOC), phos-
phoglycerate mutase 2 (PGAM2), and gamma-enolase (ENO2)
were already reduced at the age of 8 weeks, demonstrating
that the changes observed in our study occur earlier in the
disease progression. Similar results can be seen for the pro-
teins involved in glutamate-GABA-glutamine cycling, including
EAAT2, SNAT3, and GS, which also appear to be reduced
already at 8 weeks (Figure S5). Hosp et al. (2017) also observed
a temporal trend toward a reduction in glutamate decarboxylase
67 (GAD67); however, their quantitative data did not reach statis-
tical significance. Still, other studies support our findings of
diminished GAD67 expression by demonstrating reduced
mRNA levels of GAD67 in both cultured neurons derived from
induced pluripotent stem cells from HD patients (Lim et al.,
2017) as well as in the striatum from 12-week-old R6/2 mice
(Tang et al., 2011). Collectively, these results of early alterations
in metabolic protein expression may suggest that metabolic
deficits could be causal and not merely consequences of late-
stage disease progression.
Even though the expression of multiple glycolytic enzymes
was found to be downregulated (Figure 3), the regulation did
not entail functional consequences because no changes were
observed from metabolism of [U-13C]glucose (Figure S4). This
could indicate compensatory elevations in glycolytic activity
despite reduced enzyme expression. This notion is supported
by other studies in HD models, where activity or function are
affected because of altered protein location or changes in
post-translational modification (Perluigi et al., 2005; Huang
et al., 2010; Skotte et al., 2017). For the TCA cycle, we found
increased expression of two subunits in the cortex of the R6/2
mice (flavoprotein and cytochrome b) belonging to succinate de-
hydrogenase (SDH), also known as complex II of the electron2218 Cell Reports 23, 2211–2224, May 15, 2018transport chain. This is consistent with recent findings from
both HD patients and Q175 HD mice, where SDN activity
was found to be elevated in the cortex (Naseri et al., 2015).
However, other studies in both mice and humans have also
associated reductions in SDH with striatal vulnerabilities in HD
(Beal et al., 1993; Brouillet et al., 1995; Benchoua et al., 2006).
As an example, systemic injections with 3-nitroproprionic acid
(3-NP), an SDH inhibitor, results in striatal degeneration
mimicking HD pathology (Beal et al., 1993). The reason for this
discrepancy remains unclear but could be related to the nature
of the R6/2 mouse model since fluctuations in the expression
pattern of SDH have been observed previously, where SDH
was reduced at 2 weeks, increased at 4 weeks, and was again
reduced at 8 weeks (Zabel et al., 2009).
At baseline, we found increased levels of glutamine and
taurine in freshly prepared brain slices from R6/2 mice (Table
S5). The basis for the increased taurine level is still unclear, but
it may very well be a response to changes in osmolarity due to
cellular aggregation of mutant HTT protein (Foos and Wu,
2002). Taurine has several functions in the brain, including neuro-
modulatory and osmolytic effects (Foos and Wu, 2002; Menzie
et al., 2014). Taurine is also a weak GABA receptor agonist
and can reduce glutamate-induced excitotoxicity (Albrecht and
Schousboe, 2005), which has been suggested to play a central
role in neurodegeneration associated with HD (Behrens et al.,
2002; Foos and Wu, 2002; Menzie et al., 2014). Interestingly,
taurine treatment of the 3-NP model described above improved
certain behavior phenotypes as well as increased the level of
GABA (Tadros et al., 2005). In contrast to taurine, where the
mechanism behind its increase remains to be elucidated, we
propose that the increase in glutamine may be a consequence
of impaired glutamine release from astrocytes (Table S5), which
is essential for synaptic replenishment of both glutamate and
GABA.
Similar to our study, previous reports have shown decreased
expression of the astrocytic glutamate transporters EAAT1 and
EAAT2 (Behrens et al., 2002; Estrada-Sa´nchez et al., 2009;
Tong et al., 2014; Dvorzhak et al., 2016), which led to the notion
that elevated glutamate and over-activation of neuronal gluta-
mate receptors would result in enhanced neuronal susceptibility
to excitotoxic cell death (Behrens et al., 2002; Browne and Beal,
2004; Estrada-Sa´nchez et al., 2009; Tong et al., 2014; Dvorzhak
et al., 2016). As a result of these studies, augmentation of gluta-
mate uptake has been suggested as a viable therapeutic
approach for HD. However, it has recently been shown that a
brain slice preparation from R6/2 mice similar to ours exhibited
normal or even increased striatal real-time glutamate uptake
(Parsons et al., 2016). In line with this, we observed normal gluta-
mate uptake in the striatum but a slight decrease in the uptake of
glutamate in the cortex (Figure 5). Although glutamate uptake
deficiency in HD remains debated, our data suggest a more
prominent role for glutamine release in the pathogenesis of
HD. We and others have observed elevated glutamine levels in
R6/2 brains (Table S5; Behrens et al., 2002; Tsang et al., 2006;
Tkac et al., 2007; Zacharoff et al., 2012), which could either indi-
cate that astrocytic glutamine synthesis is increased or that
glutamine release is impaired. The latter is in line with reduced
expression of SNAT3 (Figure 3; Figure S5), whereas the former
Table 1. Central Protein Candidates in the R6/2 Mouse Model
Striatum Cortex Hippocampus Midbrain
Gene FC p Value Gene FC p Value Gene FC p Value Gene FC p Value
Top 25 Proteins with Decreased
Expression
Serpina1e 12.46 6.7E04 Serpina3m 18.38 1.05E03 Serpina3k 67.45 1.16E03 Serpina3k 27.80 8.12E05
Atp11b 11.68 2.7E02 Serpina1e 13.58 8.43E04 Serpina3m 47.24 2.97E04 Serpina3m 23.19 1.68E04
Serpina3k 11.13 5.4E03 Serpina3k 8.62 3.28E03 Serpina1e 17.14 8.24E04 Serpina1e 21.16 2.22E05
Myl4 9.23 4.8E05 Sdk2 6.08 1.81E02 Fkbp5 6.07 1.14E02 Prkcd 5.86 4.57E05
Serpina3m 8.22 1.5E02 Tph2 5.16 7.47E05 Rem2 5.58 1.04E02 Gjb6 5.80 1.04E04
Rasgrp2 7.87 1.2E04 Mug1 4.35 7.51E04 Hexa 4.60 2.49E02 Mug1 4.77 1.37E03
Pde10a 7.63 5.4E06 Magi3 4.33 2.18E05 Kctd4 4.40 2.38E04 Slc4a4 4.44 1.18E02
Mug1 7.60 4.3E03 Ttpal 4.09 2.15E02 Itpka 4.32 7.68E05 Grid1 4.41 5.48E03
Rgs9 7.14 3.3E04 Rasgrp2 3.87 6.84E03 Ptpn5 4.15 6.81E04 Tph2 3.87 9.71E04
Adora2a 7.08 1.7E03 Pde10a 3.81 1.94E03 Tanc1 4.03 7.72E04 Etnppl 3.76 2.79E03
Rem2 6.32 3.0E05 Ppp1r1b 3.72 6.22E05 Prkcd 4.03 1.18E02 Ckm 3.75 1.44E02
Rasd2 5.71 6.6E05 Camkk2 3.52 2.94E06 Rin1 3.95 2.45E05 Cdkl5 3.32 1.71E02
Scn4b 5.67 7.6E05 Prkcd 3.46 2.88E04 Trmt112 3.83 5.14E02 Serpina1a 3.07 5.10E03
Penk 5.12 4.5E04 Cplx3 3.45 1.41E03 Homer3 3.77 2.05E04 Pla2g7 2.97 1.53E02
Arc 5.04 1.0E02 Kctd4 3.45 1.70E03 Ppp1r16a 3.50 3.58E03 Cryab 2.77 3.77E04
Dcun1d2 5.02 1.2E02 Itpka 3.43 1.25E04 Rasgrp1 3.45 1.73E04 Slc18a2 2.71 6.92E03
Prkcd 4.76 5.2E07 Nptx2 3.38 1.58E02 Sypl1 3.31 4.70E02 Lrrtm1 2.60 1.96E03
Acy1 4.57 3.9E03 Kifc2 3.33 4.76E02 Wfs1 3.31 1.49E04 Ccdc136 2.55 4.44E03
Kcnip2 4.55 1.3E02 Eif4e2 3.20 1.73E02 Wipf3 3.27 1.35E03 Serpinb1a 2.46 3.67E04
Sec14l1 4.35 1.2E03 Pdlim1 3.17 3.29E02 Myh10 3.26 1.61E02 Syt6 2.45 1.36E03
Cyp2s1 4.31 2.9E03 Myl4 3.15 4.32E03 Tmod1 3.26 2.32E04 Fdps 2.38 3.02E04
Spata2l 4.29 1.5E04 Gfra2 3.02 4.79E02 Grin2a 3.15 3.65E05 Cyp2j9 2.38 1.17E05
Chmp1a 4.29 1.4E02 Ankrd63 2.95 1.91E02 Clic6 3.12 4.70E02 Sparc 2.31 7.75E03
Ace 4.27 6.3E02 Arc 2.78 5.20E02 Gabra5 2.98 8.25E04 Kcnj10 2.30 3.83E04
Snrpc 4.26 9.1E03 Tpm3 2.76 4.23E02 Tph2 2.95 5.15E03 9030617O03Rik 2.28 8.53E03
(Continued on next page)
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Table 1. Continued
Striatum Cortex Hippocampus Midbrain
Gene FC p Value Gene FC p Value Gene FC p Value Gene FC p Value
Top 25 Proteins with Increased
Expression
Crot 11.14 6.65E02 Chd2 46.24 1.59E02 Hap1 4.00 4.21E02 Wdr5 3.7 6.68E06
Myl6b 6.48 1.04E01 Hist3h2ba 10.99 1.05E01 Pcsk1n 2.23 1.52E04 Hist1h3a 3.2 3.08E03
Mapt 5.91 1.63E02 Gm9242 7.04 7.87E02 Gprasp1 2.20 8.60E03 Oprm1 2.8 1.30E03
Hap1 5.60 1.07E03 Slit3 6.41 8.82E02 Nova1 2.14 2.88E02 Akap8l 2.7 1.88E03
Gprasp1 5.59 1.36E03 Abca7 6.14 5.09E03 Irgm1 2.04 1.39E03 Mri1 2.6 2.29E04
Acp1 5.44 3.83E02 Cnnm3 5.32 1.04E02 Pmm2 1.96 1.16E03 Acy3 2.6 4.57E03
Copz1 5.14 5.24E02 Mapt 5.04 2.32E02 Mri1 1.87 3.98E03 Stat1 2.2 6.32E05
Ank2 4.79 1.80E02 Glrx5 5.00 4.76E02 Elavl3 1.84 1.11E02 Ftl1 2.1 6.70E04
Ftl1 4.16 2.76E02 Hap1 3.93 2.42E02 Mblac2 1.84 6.48E03 Pmm2 2.0 1.58E04
Ahi1 4.12 4.27E03 Ankle2 3.55 9.27E02 Gaa 1.81 2.02E03 Cmpk2 2.0 1.26E03
Ralyl 3.73 2.28E02 Ccdc25 3.41 8.18E02 Qrsl1 1.81 1.29E02 Irgm1 1.9 5.88E04
Amacr 3.69 1.93E02 B2m 3.38 8.23E02 Gm20498 1.76 1.30E02 Isg15 1.9 4.55E03
Fam81a 3.55 4.13E02 Eif4ebp2 3.37 5.15E02 Gng4 1.73 3.06E03 Flnb 1.9 5.92E03
Pds5a 3.25 1.96E02 Syne2 3.30 3.62E02 Fundc2 1.70 2.85E03 Cbx5 1.8 6.30E03
Mri1 3.25 6.82E06 Paf1 3.29 2.95E03 Usp4 1.70 9.44E03 Marcksl1 1.8 3.97E04
Kiaa1109 3.21 2.33E02 Fubp3 3.10 6.18E02 Cmpk2 1.70 9.96E04 Sh3bgrl 1.7 7.80E04
Cttnbp2nl 3.14 2.33E02 Cep290 3.09 8.31E02 Ctsa 1.65 1.18E03 Glo1 1.7 2.30E03
Dus3l 2.96 5.26E03 Myo9a 2.94 1.92E02 Cirbp 1.63 7.05E03 Mycbp2 1.7 5.19E04
Sf3b6 2.94 6.00E02 Crk 2.94 1.32E02 Copz1 1.61 2.49E03 Rpl37a 1.7 4.24E03
Rlbp1 2.94 5.82E02 Nudt12 2.92 2.95E03 Enpp6 1.60 8.29E03 Vwa5a 1.6 1.61E03
Map3k4 2.86 4.82E02 Mri1 2.85 8.19E05 Ublcp1 1.60 2.37E03 Psmd4 1.6 3.60E03
Macrod1 2.84 1.96E05 Rwdd1 2.85 5.46E03 Fbxo22 1.60 2.24E04 Luc7l2 1.6 5.27E04
Elavl2 2.77 2.98E03 Dcc 2.79 1.82E02 Ralyl 1.59 2.11E02 D3Ertd751e 1.6 1.90E03
Tstd3 2.77 7.92E02 Gprasp1 2.77 1.38E02 Scrn2 1.58 1.78E02 Rnpep 1.6 9.68E04
Cnot2 2.76 2.31E02 Rp2 2.70 6.36E02 Ptprn 1.56 5.06E03 M6pr 1.6 3.05E03
The proteins with the largest differential expression for each brain regions are shown for proteins with both increased and decreased expression in R6/2 compared with WTmice. The expression
difference is stated as log2 fold change (FC), and the associated p value is illustrated.
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appears less likely since we and others have observed
decreased expression of GS in R6/2 brains (Lie´vens et al.,
2002; Boussicault et al., 2014; Tong et al., 2014). Furthermore,
we did not observe reductions in glutamine labeling or levels af-
ter incubation with either [U-13C]glutamate or [U-13C]glutamine,
indicating normal GS activity and glutamine uptake, respectively.
Overall, these results point toward dysfunctional astrocytic
glutamine release, which may, in turn, explain the reduced
neuronal GABA labeling observed after [U-13C]glutamate or
[1,2-13C]acetate incubation (Sonnewald et al., 1993; Figures 4
and 5), consistent with reduced cerebral GABA levels in HD pa-
tients (Spokes et al., 1980; Patassini et al., 2016). Under baseline
conditions, we observed a trend toward reduced GABA levels in
striatal slices of R6/2 mice (Table S5), which supports neurode-
generation in this region, and since striatal neurons from R6/2
mice are more vulnerable compared with WT mice, it could be
argued that a fraction of these neurons would be more suscep-
tible to stress during the preparation of brain slices and cause
the observed reduced 13C labeling in GABA (Table S6). However,
the percentage of 13C labeling is calculated in relation to the total
amount of the respective metabolite (Walls et al., 2014), and
since the total cellular GABA amounts were unchanged in the ex-
tracts of the incubated slices from R6/2 and WT mice, the
reduced 13C enrichment in GABA is most likely due to reduced
synthesis rather than reduced viability of GABAergic neurons
in brain slices from R6/2 mice. This is also consistent with previ-
ous work demonstrating that brain slices can remain metaboli-
cally viable for up to 12 hr under appropriate conditions
(Rae, 2014). Second, it could be discussed whether the findings
are a consequence of neuronal loss because we are looking
at end-stage R6/2mice. Here, the previous notion of 13C labeling
normalization also applies, and this is further substantiated
by normal GABA labeling after 60 min of incubation with
either [U-13C]glucose, [U-13C]bHB, and [U-13C]glutamine, indi-
cating viable brain slices, in contrast to incubation with [1,213C]
acetate or [U-13C]glutamate, displaying significant astrocytic
impairments.
The suggestion that the astrocyte is the culprit in HD is in line
with recent studies showing impaired neuronal metabolism
when co-cultured with astrocytes expressingmutant HTT (Bous-
sicault et al., 2014), whereas metabolism is not noticeably
affected in neurons from HD mouse models cultured alone
(Boussicault et al., 2014; Hamilton et al., 2015, 2016). Further-
more, it has been shown that transplanted human astrocytes
expressing mutant HTT can induce a HD pathology-like state
in healthy mice, whereas transplanted healthy astrocytes can
alleviate HD symptoms in R6/2 mice (Benraiss et al., 2016).
Our results indicate that metabolic defects are more promi-
nent in astrocytes compared with neurons in the R6/2 brain
and may take place as early as 8 weeks of age (Figure S5). How-
ever, since we used end-stage R6/2 mice for this study, we
cannot conclude with certainty whether the astrocytic metabolic
dysfunctions are part of the cause or a consequence of disease
progression. Hence, functional metabolic follow-up studies at
pre-symptomatic and early stages of the disease are desired
to assess how early astrocytic metabolism is affected in R6/2
mice. In addition, validation of our findings in full-length HTT
transgenic or knockin mouse models of HD, which displayslower disease progression, would be of high scientific value
and interest.
Collectively, our study shows that proteomics and 13C map-
ping in combination are powerful tools to dissectmetabolic path-
ways. Our data suggest that astrocytes could be a central driver
behind HD pathology as result of impaired metabolism and
glutamine release, leading to diminished neuronal GABA synthe-
sis. This would lead to impaired inhibitory neurotransmission
and, in turn, enhance the detrimental excitatory neurotransmis-
sion observed in HD. Hence, our data suggest that normalizing
astrocyte metabolism may be a beneficial approach to restore
or improve neuronal function in HD.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in the
Supplemental Experimental Procedures.
Mouse Strains
R6/2, transgenic for exon 1 of the human HTT gene (Mangiarini et al., 1996),
originated from The Jackson Laboratory (Bar Harbor, Maine, USA) and were
maintained by backcrossingmales to CBA/j3B6 females (Taconic, Denmark).
The mice were kept under specific pathogen-free conditions at a 12 hr light/
12 hr darkness cycle in standard polystyrene cages with ad libitum access
to standard chow and water. DNA was extracted from ear punches and
used for genotyping (Andrew et al., 1994). The repeat length was between
190–200 CAG throughout the experiment. 12-week-old male mice were
used for both proteomic and metabolic analysis. WT littermates without the
HTT transgene were used as controls.
Statistical Analysis
The statistical tests are annotated in the figure legends and/or in the Supple-
mental Experimental Procedures for the specific analysis. The mean, SD,
SEM, and significance levels are reported in the tables, figures, and/or in the
legends. Statistical analyses for proteome data were performed using Perseus
as described in the Supplemental Experimental Procedures for each individual
analysis. Statistical analyses for brain slice incubation data were done in Prism
7, and the results are presented as means ± SEM. Outliers were identified
using Grubb’s outlier test (a = 0.05). Statistical differences were tested using
Student’s unpaired t test, with a significance level of p < 0.05 indicated by a
single asterisk. The exact p values can also be found in Tables S5 and S6.
Ethical Approval
Experiments were performed in accordance with the Danish Animal Experi-
ments Inspectorate’s guidelines (permit 2007/561-1345), the Danish Working
Environment Authority (permit 20070033239/4), and European Commission
Directive 86/609/EEC for animal experiments.
DATA AND SOFTWARE AVAILABILITY
The accession number for the MS-based proteomics data reported in this
paper is ProteomeXchange Consortium: PXD008099.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and six tables and can be found with this article online at https://
doi.org/10.1016/j.celrep.2018.04.052.
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